By Cristina de Min (Topas Therapeutics)2024-10-16T10:00:30
Driven by a passion for early-stage scientific discovery, Cristina de Min, MD, Chief Medical Officer at Topas Therapeutics, transitioned from clinical practice to drug development. Her expertise has played a pivotal role in advancing new treatments, with her achievements demonstrating her commitment to improving patient outcomes.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-26T13:58:00Z
2024-01-26T13:22:42
Sponsored by bit.bio
2024-03-08T10:00:25
Sponsored by Molecular Devices
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2023-07-04T10:05:58
Sponsored by Revvity
2023-03-30T12:35:58
Sponsored by Sartorius
Site powered by Webvision Cloud